SuperworthAmarin Corp Plc profit margin AMRN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −14.6%
- Operating margin, 12 months
- −21.9%
- Net margin on a year earlier
- +32.7 pts
- Peer median
- 13.6%
Over the twelve months to Jun 30, 2026, Amarin Corp Plc kept −14.6% of its revenue as net profit, with an operating margin of −21.9% and a gross margin of 42.0%.
Five years earlier its net margin was 0.7%.
The median for 10 large drugmakers of a similar size is 13.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −18.2% | −23.5% | 56.6% |
| FY2024 | −35.9% | −40.2% | 35.6% |
| FY2023 | −19.3% | −22.0% | 53.9% |
| FY2022 | −28.7% | −28.7% | 65.7% |
| FY2021 | 1.3% | 1.8% | 79.2% |
| FY2020 | −2.9% | −3.2% | 78.6% |
| FY2019 | −5.3% | −5.6% | 77.7% |
| FY2018 | −50.8% | −47.2% | 76.2% |
| FY2017 | −37.5% | −25.2% | 75.2% |
| FY2016 | −66.4% | −50.4% | 73.6% |
| FY2015 | n/a | n/a | 65.9% |
| FY2014 | n/a | n/a | 62.2% |
| FY2013 | n/a | n/a | 54.8% |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −14.6% | +32.7 pts | −21.9% | |
| Q1 FY26 | −15.5% | +25.6 pts | −20.6% | |
| Q4 FY25 | −18.2% | +17.8 pts | −23.5% | |
| Q3 FY25 | −38.0% | −21.7 pts | −42.5% | |
| Q2 FY25 | −47.2% | −34.6 pts | −50.3% | |
| Q1 FY25 | −41.1% | −22.1 pts | −44.4% | |
| Q4 FY24 | −35.9% | −16.7 pts | −40.2% | |
| Q3 FY24 | −16.3% | −0.1 pts | −18.3% | |
| Q2 FY24 | −12.7% | −1.6 pts | −15.3% | |
| Q1 FY24 | −19.0% | +6.2 pts | −23.0% | |
| Q4 FY23 | −19.3% | +9.4 pts | −22.0% | |
| Q3 FY23 | −16.3% | +5.4 pts | −22.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Amarin Corp Plc's size, closest first, today.
| Company | Profit margin |
|---|---|
| AMRNAmarin Corp Plc | −14.6% |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| Peer median | 13.6% |
Where Amarin Corp Plc ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Amarin Corp Plc
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.